NL13, a Polo-like kinase 4 (PLK4) inhibitor, exhibits an IC 50 value of 2.32 µM. It demonstrates the ability to suppress the viability of PC3 and DU145 prostate cancer cells with respective IC 50 values of 3.51 µM and 2.53 µM. NL13 also inhibits tumor growth in prostate cancer mice. Additionally, it deactivates the AKT signaling pathway by reducing CCNB1/CDK1 levels, leading to G2/M cell cycle arrest and initiating apoptosis through caspase-9/caspase-3 cleavage.
Molecular Weight:
400.3
Formula:
C22H19Cl2NO2
Target:
PLK|||Apoptosis|||Akt|||Caspase|||CDK
* VAT and and shipping costs not included. Errors and price changes excepted
